219 related articles for article (PubMed ID: 27523969)
21. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features.
Bartosch C; Manuel Lopes J; Oliva E
Adv Anat Pathol; 2011 Nov; 18(6):415-37. PubMed ID: 21993268
[TBL] [Abstract][Full Text] [Related]
22. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
23. Morphological and Immunohistochemical Reevaluation of Tumors Initially Diagnosed as Ovarian Endometrioid Carcinoma With Emphasis on High-grade Tumors.
Lim D; Murali R; Murray MP; Veras E; Park KJ; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):302-12. PubMed ID: 26551621
[TBL] [Abstract][Full Text] [Related]
24. HMGA2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis.
McCluggage WG; Connolly LE; McBride HA; Kalloger S; Gilks CB
Histopathology; 2012 Mar; 60(4):547-53. PubMed ID: 22250726
[TBL] [Abstract][Full Text] [Related]
25. Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases.
Köbel M; Meng B; Hoang LN; Almadani N; Li X; Soslow RA; Gilks CB; Lee CH
Am J Surg Pathol; 2016 Feb; 40(2):166-180. PubMed ID: 26492180
[TBL] [Abstract][Full Text] [Related]
26. Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?
Fadare O; Roma AA; Parkash V; Zheng W; Walavalkar V
Adv Anat Pathol; 2018 Jan; 25(1):61-70. PubMed ID: 28945609
[TBL] [Abstract][Full Text] [Related]
27. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
Irving JA; Catasús L; Gallardo A; Bussaglia E; Romero M; Matias-Guiu X; Prat J
Hum Pathol; 2005 Jun; 36(6):605-19. PubMed ID: 16021566
[TBL] [Abstract][Full Text] [Related]
28. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
29. Morphologic Reproducibility, Genotyping, and Immunohistochemical Profiling Do Not Support a Category of Seromucinous Carcinoma of the Ovary.
Rambau PF; McIntyre JB; Taylor J; Lee S; Ogilvie T; Sienko A; Morris D; Duggan MA; McCluggage WG; Köbel M
Am J Surg Pathol; 2017 May; 41(5):685-695. PubMed ID: 28125452
[TBL] [Abstract][Full Text] [Related]
30. Sarcomatous Transformation in Undifferentiated/Dedifferentiated Endometrial Carcinoma: An Underrecognized Phenomenon and Diagnostic Pitfall.
Vroobel KM; Attygalle AD
Int J Gynecol Pathol; 2020 Sep; 39(5):485-492. PubMed ID: 31567540
[TBL] [Abstract][Full Text] [Related]
31. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
32. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.
Meng B; Hoang LN; McIntyre JB; Duggan MA; Nelson GS; Lee CH; Köbel M
Gynecol Oncol; 2014 Jul; 134(1):15-9. PubMed ID: 24844595
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
[TBL] [Abstract][Full Text] [Related]
34. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
[TBL] [Abstract][Full Text] [Related]
35. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes.
Garg K; Leitao MM; Wynveen CA; Sica GL; Shia J; Shi W; Soslow RA
Mod Pathol; 2010 Jan; 23(1):80-92. PubMed ID: 19855378
[TBL] [Abstract][Full Text] [Related]
36. Molecular staging of gynecological cancer: What is the future?
Binder PS; Prat J; Mutch DG
Best Pract Res Clin Obstet Gynaecol; 2015 Aug; 29(6):776-89. PubMed ID: 25934522
[TBL] [Abstract][Full Text] [Related]
37. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type.
Clarke BA; Gilks CB
J Clin Pathol; 2010 May; 63(5):410-5. PubMed ID: 20418232
[TBL] [Abstract][Full Text] [Related]
38. Molecular analysis in endometrial cancer.
Caduff RF; Svoboda-Neumann SM; Johnston CM; Bartos RE; Frank TS
Verh Dtsch Ges Pathol; 1997; 81():219-27. PubMed ID: 9474873
[TBL] [Abstract][Full Text] [Related]
39. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
40. Expression of PTEN in endometrial liquid-based cytology.
Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
